



IFW

PATENT
Attorney Docket No. 25734X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

POPP

Serial No.: 10/791,839

Filing Date: March 4, 2004

For: **ANTIMICROBIAL TOPICAL COMPOSITIONS FOR TREATMENT
OF ROSACEA**

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith for filing in the U.S. Patent and
Trademark Office is the following:


- 1) Transmittal Letter;
- 2) Supplemental Information Disclosure Statement;
- 3) PTO-Form 1449; and
- 4) Five (5) References Cited.

The Commissioner is specifically authorized to charge any required fee deficiency under 37 CFR §§ 1.16 or 1.17, or credit any overpayment, to Deposit Account No. 14-0112 in connection with this matter.

Respectfully submitted,

NATH & ASSOCIATES PLLC

Date: July 12, 2004
NATH & ASSOCIATES PLLC
1030 Fifteenth Street, N.W.
Sixth Floor
Washington, D.C. 20005
Tel: (202) 775-8383
Fax: (202) 775-8396
GMN:JBG:\1sids-t1.doc



Gary M. Nath
Reg. No. 26,965
Joshua B. Goldberg
Reg. No. 44,126
Customer No. 20529



PATENT
Attorney Docket No. 25734X

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

POPP

Serial No.: 10/791,839

Filing Date: March 4, 2004

For: ANTIMICROBIAL TOPICAL COMPOSITIONS FOR TREATMENT OF
ROSACEA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

[X] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. § 1.17(p).

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
[] Certification report(e) below; and
[] a check in the amount as required by § 1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[X] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[X] g. Copies of the non-U.S. patent documents are attached herewith with a completed Form PTO-1449.

or


[] Copies of the documents are not attached as allowed under CFR § 1.98(d)(1)(2). The earlier application is identified as:

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.


If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:


Gary M. Nath
Registration No. 26,965
Joshua B. Goldberg
Registration No. 44,126
Customer No. 20529

Date: July 12, 2004
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005-1503
Tel. (202) 775-8383
Fax. (202) 775-8396
GMN:JBG (1SIDS.doc)



FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAtty. Docket
25734XSerial No.
10/791,839

Applicant

POPP

Filing Date
March 4, 2004Group Art Unit
1648

U. S. PATENT DOCUMENTS

Examiner Initial	Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub-Class	Trans-lation
AJ						
AK						
AL						
AM						
AN						
AO						
AP						
AQ						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		Laude et al., "Perioral Dermatitis in Children", <u>Semin. Cutan. Med. Surg.</u> , 1999, 18(3), 206-209.
AS		Hogan et al., "Perioral dermatitis: an uncommon condition?", <u>CMAJ</u> , 1986, 134, 1025-1028.
AT		Dahl et al., "Temperature regulates bacterial protein production: Possible role in rosacea", <u>J. Am. Acad. Dermatol.</u> , 2004, 50(2), 266-272.
AU		Wilkin et al., "Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea", <u>J. Am. Acad. Dermatol.</u> , 2002, 46(4), 584-587.
AV		Wilkin, "Rosacea: Pathophysiology and Treatment", <u>Arch. Dermatol.</u> , 1994, 130, 359-362.

Examiner	Date Considered